Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) insider Mark Jeffrey Delong sold 363 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $28.54, for a total transaction of $10,360.02. Following the sale, the insider now directly owns 83,945 shares of the company's stock, valued at approximately $2,395,790.30. This represents a 0.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Apellis Pharmaceuticals Trading Down 0.2 %

Shares of Apellis Pharmaceuticals stock traded down $0.06 during trading on Friday, hitting $27.40. The stock had a trading volume of 1,287,866 shares, compared to its average volume of 1,715,733. The firm's fifty day simple moving average is $31.21 and its 200-day simple moving average is $32.09. The stock has a market cap of $3.41 billion, a PE ratio of -13.50 and a beta of 0.96. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on APLS shares. Citigroup dropped their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a "neutral" rating for the company in a research report on Thursday, October 24th. Evercore ISI upgraded shares of Apellis Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, October 31st. Scotiabank dropped their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a "sector perform" rating for the company in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company dropped their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating for the company in a research report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently made changes to their positions in APLS. Braidwell LP lifted its holdings in shares of Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company's stock worth $90,130,000 after acquiring an additional 2,513,383 shares during the last quarter. Boxer Capital Management LLC purchased a new position in Apellis Pharmaceuticals in the 4th quarter worth about $45,504,000. Assenagon Asset Management S.A. increased its stake in Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company's stock worth $61,845,000 after buying an additional 1,409,707 shares during the period. National Bank of Canada FI increased its stake in Apellis Pharmaceuticals by 266,361.5% in the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock worth $44,214,000 after buying an additional 1,385,080 shares during the period. Finally, Cibc World Markets Corp purchased a new position in Apellis Pharmaceuticals in the 4th quarter worth about $41,014,000. Institutional investors own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).